Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Forsøg mod uhelbredelig type 2-diabetes (CAPTAIN-T2D) (CAPTAIN-T2D)

5. oktober 2026 opdateret af: Sparrow Pharmaceuticals

Clofutriben og Placebo Fase 2 Studie Mod INtractabel Type 2 Diabetes (CAPTAIN-T2D)

CAPTAIN-T2D will take place in two parts. Part 1 (Screening) will evaluate patients with type 2 diabetes and elevated cortisol risk factors for trial eligibility and the presence of elevated cortisol. Participants deemed eligible from Part 1 will be randomized to either clofutriben or placebo in the double-blind (participant and investigator), dose-ranging, interventional Part 2 (Treatment).

Studieoversigt

Status

Rekruttering

Detaljeret beskrivelse

CAPTAIN-T2D is a two-part, multicenter, randomized, double-blind, parallel group, placebo- controlled trial of the 11-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor clofutriben. The primary objectives of this trial are to characterize the relationship of clofutriben dose to improved glycemic control, and to identify one or more doses suitable for Phase 3 evaluation, in patients with T2D and elevated cortisol.

The trial consists of two parts.

Part 1 (Screening) will last between approximately 5 to 9 weeks for most participants. The screening period duration allows for (sequentially) initial eligibility screen, dexamethasone suppression test, and further eligibility assessments.

During Part 2 (Treatment), participants will be randomized to placebo or one of four clofutriben doses. Part 2 will last 24 weeks with a follow-up phone call 4 weeks after the last dose of trial medication.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

1500

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Arizona
      • Chandler, Arizona, Forenede Stater, 85225
      • Tucson, Arizona, Forenede Stater, 85711
    • California
      • Fountain Valley, California, Forenede Stater, 92708
        • Rekruttering
        • Ark Clinical Research - Fountain Valley
        • Kontakt:
      • Huntington Park, California, Forenede Stater, 90255
      • La Mesa, California, Forenede Stater, 91942
      • Long Beach, California, Forenede Stater, 90815
      • Los Angeles, California, Forenede Stater, 90057
      • Los Angeles, California, Forenede Stater, 90015
        • Rekruttering
        • Los Angeles Institute for Metabolic Research
        • Kontakt:
      • Northridge, California, Forenede Stater, 98433
      • San Diego, California, Forenede Stater, 92120
    • Florida
      • Edgewater, Florida, Forenede Stater, 32132
      • Fort Lauderdale, Florida, Forenede Stater, 33312
        • Rekruttering
        • The Center for Diabetes and Endocrine Care
        • Kontakt:
      • Miami, Florida, Forenede Stater, 33173
      • New Port Richey, Florida, Forenede Stater, 34652
      • Port Charlotte, Florida, Forenede Stater, 33952
        • Rekruttering
        • Innovative Research Institute
        • Kontakt:
      • Port Orange, Florida, Forenede Stater, 32127
      • Winter Park, Florida, Forenede Stater, 32789
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30303
        • Rekruttering
        • Emory University School of Medicine
        • Kontakt:
      • Columbus, Georgia, Forenede Stater, 31904
    • Idaho
      • Boise, Idaho, Forenede Stater, 83709
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60607
        • Rekruttering
        • Chicago Clinical Research Institute
        • Kontakt:
          • Manognya Clinical Research Manager
          • Telefonnummer: 303 3127913241
          • E-mail: manognya@ccrii.us
    • Iowa
      • West Des Moines, Iowa, Forenede Stater, 50226
        • Rekruttering
        • Iowa Diabetes and Endocrinology Research Center
        • Kontakt:
    • Kansas
      • Wichita, Kansas, Forenede Stater, 67226
        • Rekruttering
        • Alliance for Multispecialty Research - Wichita East
        • Kontakt:
    • Kentucky
      • Edgewood, Kentucky, Forenede Stater, 41017
    • Louisiana
      • Lafayette, Louisiana, Forenede Stater, 70508
      • Metairie, Louisiana, Forenede Stater, 70006
        • Rekruttering
        • NOLA Care Clinical Research
        • Kontakt:
      • New Orleans, Louisiana, Forenede Stater, 70112
        • Rekruttering
        • Tulane University School of Medicine
        • Kontakt:
    • Maryland
      • Rockville, Maryland, Forenede Stater, 20854
    • Massachusetts
      • Springfield, Massachusetts, Forenede Stater, 011030
    • Michigan
      • Troy, Michigan, Forenede Stater, 48085
        • Rekruttering
        • Oakland Medical Research Center
        • Kontakt:
    • Nebraska
      • Lincoln, Nebraska, Forenede Stater, 68510
      • Omaha, Nebraska, Forenede Stater, 68134
    • Nevada
      • Las Vegas, Nevada, Forenede Stater, 89148
      • Las Vegas, Nevada, Forenede Stater, 89108
    • New York
      • Albany, New York, Forenede Stater, 12203
        • Rekruttering
        • Albany Medical College
        • Kontakt:
    • North Carolina
      • Chapel Hill, North Carolina, Forenede Stater, 27514
        • Rekruttering
        • University of North Carolina at Chapel Hill
        • Kontakt:
      • Greenville, North Carolina, Forenede Stater, 27834
      • Morehead City, North Carolina, Forenede Stater, 28557
      • Wilmington, North Carolina, Forenede Stater, 28401
        • Rekruttering
        • PMG Research of Wilmington, LLC
        • Kontakt:
    • Ohio
      • Cincinnati, Ohio, Forenede Stater, 45219
        • Rekruttering
        • Velocity Clinical Research, Cincinnati, Mt. Auburn
        • Kontakt:
      • Cincinnati, Ohio, Forenede Stater, 45242
        • Rekruttering
        • Velocity Clinical Research - Cincinnati, Blue Ash
        • Kontakt:
      • Columbus, Ohio, Forenede Stater, 43201
      • Columbus, Ohio, Forenede Stater, 43215
        • Rekruttering
        • Remington Davis, Inc
        • Kontakt:
    • Oregon
      • Eugene, Oregon, Forenede Stater, 97404
        • Rekruttering
        • Willamette Valley Clinical Studies
        • Kontakt:
    • Pennsylvania
      • West Chester, Pennsylvania, Forenede Stater, 19380
    • South Carolina
      • Anderson, South Carolina, Forenede Stater, 29621
      • Mt. Pleasant, South Carolina, Forenede Stater, 29464
    • Texas
      • Austin, Texas, Forenede Stater, 78759
      • Dallas, Texas, Forenede Stater, 75230
      • Houston, Texas, Forenede Stater, 77040
      • Lampasas, Texas, Forenede Stater, 76550
        • Rekruttering
        • Radiance Clinical Research
        • Kontakt:
      • Lewisville, Texas, Forenede Stater, 75057
      • Mission, Texas, Forenede Stater, 78572
        • Rekruttering
        • Texas Valley Clinical Research - Mission, TX
        • Kontakt:
      • Round Rock, Texas, Forenede Stater, 78681
        • Rekruttering
        • Texas Diabetes & Endocrinology, P.A. - Round Rock
        • Kontakt:
      • San Antonio, Texas, Forenede Stater, 78229
        • Rekruttering
        • Diabetes & Glandular Disease Clinic, P.A.
        • Kontakt:
      • San Antonio, Texas, Forenede Stater, 78251
        • Rekruttering
        • Texas Valley Clinical Research - San Antonio TX
        • Kontakt:
      • Seabrook, Texas, Forenede Stater, 77586
      • Weslaco, Texas, Forenede Stater, 78596
        • Rekruttering
        • Texas Valley Clinical Research, LLC
        • Kontakt:
    • Utah
      • West Jordan, Utah, Forenede Stater, 84088
        • Rekruttering
        • Velocity Clinical Research, Salt Lake City
        • Kontakt:
    • Virginia
      • Suffolk, Virginia, Forenede Stater, 23435
      • Vienna, Virginia, Forenede Stater, 22182

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • From Screening 1

    • Age at least 18 years.

    • HbA1c ≥7.5% documented within 3 months prior to Screening 1. (The historical HbA1c value must have been obtained after at least 2 months on the current [as of Screening 1] regimen).

    • Treatment with stable and adequate doses of ≥2 injectable or oral ADMs. (An ADM will be deemed stable if the dose has been the same for at least 3 months prior to Screening 1 and without change between Screening 1 and Day 1) (An ADM dose will be deemed adequate if it is at or above the maximal labelled dose, or a sub-maximal, but not starting, dose if limited by tolerability (confer with MM if less than half-maximal dose).

    • Adequate total daily insulin is defined as at least 0.3 units/kg/day. Insulin dose will be deemed stable with adjustments of up to 20% total daily dose during the 3 months prior to Screening 1 or between Screening 1 and Day 1.

    • Use of insulin pumps or insulin brand changes (e.g., due to insurance change or shortage) are to be discussed with the MM.

    • At least one of the following

      • ≥3 stable and adequate ADMs;
      • diabetes complication (retinopathy, nephropathy, neuropathy, atherosclerotic heart disease);
      • hypertension requiring ≥2 adequately dosed AHMs;
      • adequately dosed basal or basal plus prandial insulin in addition to at least 1 other ADM; and
      • adequately dosed incretin agonist (a single or combination agent counts as one ADM) in addition to at least 1 other ADM;
      • evidence or history of osteoporosis or non-traumatic fracture (e.g., vertebral body compression);
      • or established diagnosis of a neoplastic (non-malignant) source of hypercortisolism and have failed, are ineligible for, or declined surgery.

At DST • Post-DST cortisol level >1.8 µg/dL and serum dexamethasone ≥140 ng/dL. Patients with an established diagnosis of neoplastic hypercortisolism do not require a DST.

At Screening 2

  • HbA1c ≥7.5% at Screening 2. At Day 1
  • No change in, or initiation of, medications for hypertension within 1 month prior to Day 1.

Exclusion Criteria:

  • New-onset diabetes (onset <1 year in the past).

  • Unwillingness to maintain with current glucose-lowering regimen during the trial.

  • Unwillingness to adjust, add, replace, or discontinue current or other glucose-lowering medications during the trial as directed by the investigator.

  • Unwillingness to comply with CGM or other trial procedures.

  • Investigator considers the patient will otherwise be unwilling or unable to complete the trial.

  • Night-shift worker or otherwise habitually awake from 23:00 to 07:00 h.

  • Evidence for significant hypoglycemia while on their current diabetic treatment regimen(This includes episodes of symptomatic Level 3 hypoglycemia requiring external assistance for recovery, or CGM-documented prolonged [>15 min] or repeated episodes of either Level 2 hypoglycemia leading to >1%, or Level 1 hypoglycemia leading to >4%, in "time below range" within 3 months prior to Screening 1 or between Screening 1 and Day 1).

  • Any of the following in medical history:

    • Type 1 diabetes mellitus (T1D), latent autoimmune diabetes in adults (LADA), or familial forms of maturity-onset diabetes of the young (MODY);
    • A hemoglobinopathy or other condition which may interfere with measurement of HbA1c (e.g., sickle cell disease HbSS or other variants HbEE thalassemia, hemolytic anemia, recent blood transfusion);
    • Hypersensitivity or severe reaction to dexamethasone;
    • Pheochromocytoma, or suspicion thereof;
    • Anorexia, or other eating disorder;
    • Glucocorticoid resistance;
    • Multiple sclerosis;
    • Significant hepatic impairment (e.g., Child-Pugh Class B or C);
    • Idiopathic thrombocytopenic purpura;
    • Untreated or inadequately controlled moderate-to-severe sleep apnea (apnea-hypopnea index ≥15). (Patients whose condition has been well controlled with Continuous Positive Airway Pressure (CPAP) use for at least 3 months prior to Screening 1 are not excluded. Patients with a STOP-BANG score 5-8 should be referred for a sleep study outside the trial and may rescreen if found not to have moderate-to-severe sleep apnea);
    • Current alcohol consumption >14 units/week or >4 units in a single day for males, or >7 units/week or >3 units in a single day for females. (Patients with a CAGE score 2-4 should be evaluated further outside the trial and may be rescreened if found not to have an alcohol [or other substance] use disorder);
    • Untreated or inadequately controlled major depressive disorder, generalized anxiety disorder, bipolar disorder, post-traumatic stress disorder, or schizophrenia.(Patients whose condition has been well controlled with stable medical therapy, or has been asymptomatic, for at least 3 months prior to Screening 1 are not excluded); or
    • Any other medical condition (including malignancy) that is likely to interfere with trial assessments or the patient's ability to complete the trial.
    • Any of the following in medication history:
    • Any of the excluded medications listed in Section 6.9;
    • Any investigational drug within 4 weeks or within less than five times the drug's half-life, whichever is longer, prior to Screening 1 or between Screening 1 and Day 1;
    • Woman of childbearing potential (WOCBP) not willing to adhere to highly effective contraception or strict abstinence for the duration of the trial and for 90 days post completion/discontinuation; and
    • Pregnancy (including a positive urine test) or current breast feeding.

From Screening 2

• Prior probability of undiagnosed endogenous Cushing syndrome based on either of:

  • wo morning serum cortisol values after dexamethasone suppression >5.0 mcg/dL together with plasma dexamethasone >140 ng/mL; or
  • a morning serum cortisol value after dexamethasone suppression >1.8 mcg/dL, together with plasma dexamethasone >140 ng/mL and any one of the following that is not attributable to an etiology other than endogenous Cushing's syndrome:
  • supraclavicular/dorsocervical fat accumulation;
  • irounding of the face (especially compared with prior photos);
  • skin changes (violaceous striae, skin thinning, or excessive bruising);
  • proximal muscle weakness on exam; or
  • history of deep vein thrombosis/pulmonary embolism.
  • Plans for, or medically unable to forego, treatment for endogenous Cushing syndrome or ACS within the next 8 months. (For clarity, patients with EnCS or ACS, not having such treatment plans, and medically able to forego treatment for 8 months may enroll if otherwise eligible).
  • Severe, poorly controlled hypertension (mean systolic BP >160 mmHg or mean diastolic BP >100 mmHg) at Screening 2 or between Screening 2 and Day 1, including by at-home monitoring. (Such patients will be eligible to rescreen for Part 2 when they restore BP <160/100 mmHg for 1 month on a new stable medication regimen).
  • Positive urine screen for recreational drugs (except tetrahydrocannabinol (THC)).
  • Glomerular filtration rate (GFR) (determined using Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) <45 mL/min/1.73 m².
  • Poorly controlled hyperthyroidism/hypothyroidism (confirmed by TSH or Free thyroxine [fT4]).
  • Liver enzymes >3 × upper limit of normal (ULN) (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or bilirubin >1.5 × ULN.(excepting benign conditions such as Gilbert's)
  • Known hypersensitivity to clofutriben or to any of the product

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Andet
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Dose 1

clofutriben .2 mg oral tablet daily

HSD-1 inhibitor

Andre navne:
  • SPI-62
  • ASP3662
Eksperimentel: Dose 2

clofutriben 2mg oral tablet daily

HSD-1 inhibitor

Andre navne:
  • SPI-62
  • ASP3662
Eksperimentel: Dose 3

clofutriben 6mg oral tablet daily

HSD-1 inhibitor

Andre navne:
  • SPI-62
  • ASP3662
Eksperimentel: Dose 4

clofutriben 12 mg oral tablet daily

HSD-1 inhibitor

Andre navne:
  • SPI-62
  • ASP3662
Placebo komparator: placebo

placebo control oral tablet daily

Placebo

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percentage of patients with both morning serum cortisol >1.8 mg/dL and morning plasma dexamethasone >=140 ng/dL (single composite endpoint) after a single dexamethasone 1 mg dose taken the prior night.
Tidsramme: 8-10 hours after the dexamethasone 1 mg dose.

To assess prevalence in the trial population of morning cortisol non-suppression by a single dexamethasone 1 mg dose.

8-10 hours after the dexamethasone 1 mg dose.
Glycated hemoglobin A1c (%) change from baseline to Week 24 by treatment.
Tidsramme: 24 weeks.

To assess glycated hemoglobin A1c (%) changes, compared to placebo, in patients who receive each of 4 daily clofutriben doses for 24 weeks.

24 weeks.

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Fasting plasma glucose (mmol/L) change from baseline to Week 24 by treatment.
Tidsramme: 24 weeks

To assess glucose (mmol/L) changes, compared to placebo, in patients who receive each of 4 daily clofutriben doses for 24 weeks.

24 weeks

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
To evaluate the safety of clofutriben in participants with T2D and EC.
Tidsramme: From enrollment until end of trial 9 month

Frequency of TEAEs (treatment-emergent adverse even) by clofutriben dose

From enrollment until end of trial 9 month

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

29. november 2025

Primær færdiggørelse (Anslået)

31. december 2027

Studieafslutning (Anslået)

30. juni 2028

Datoer for studieregistrering

Først indsendt

30. november 2025

Først indsendt, der opfyldte QC-kriterier

18. december 2025

Først opslået (Faktiske)

22. december 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

6. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

5. oktober 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner